Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. - Wikidata - awgldk - TriplyDB

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.

http://www.wikidata.org/entity/Q35013781

about

Population pharmacokinetics of abacavir in pregnant women.Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?In vitro-in vivo correlation of efavirenz tablets using GastroPlus®Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.

P2860

Q34299084-C2F93B3D-29EC-4C50-AC82-C487D1805C8B Q35018246-24FD2F12-1001-443B-8851-C85517AED1DC Q35024683-57C8F6C2-3569-4701-A632-9F1BF7C7F9F2 Q35233168-FC59B4B8-94AF-405B-8B6D-5236789ED917 Q35826765-CB299415-7291-4026-B286-E28722EAB28A Q36723853-E77AF7C5-5BA4-4881-A939-F3A8B82EF192 Q37126427-12236455-CCD3-4081-AC71-04644D288967 Q37489345-B4414AA0-9F0D-494B-8B62-A4708BF90FE1 Q37598636-8908DD2F-CB57-45D3-95A2-36B61927804D

P2860

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.

http://www.wikidata.org/entity/Q35013781

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Indinavir, efavirenz, and abac ...... iency virus-infected subjects.

@ast

Indinavir, efavirenz, and abac ...... iency virus-infected subjects.

@en

type

label

Indinavir, efavirenz, and abac ...... iency virus-infected subjects.

@ast

Indinavir, efavirenz, and abac ...... iency virus-infected subjects.

@en

prefLabel

Indinavir, efavirenz, and abac ...... iency virus-infected subjects.

@ast

Indinavir, efavirenz, and abac ...... iency virus-infected subjects.

@en

P1433

Q35013781-D565597A-2D57-4101-927D-30D65FBFE01C

P1476

Q35013781-C88D9E02-7902-4C32-A564-915F55AF5F4D

P2093

Q35013781-28202E18-9EE3-4FBB-A806-6C8B635F4548

Q35013781-3E752B8E-382D-4E2C-9601-23EE05AC6838

Q35013781-7CD56578-5CFC-43FB-A9B9-7FD4933E71B8

Q35013781-9B96F32D-AC6E-4398-A4F7-5C08D56E9BC5

Q35013781-BA68311B-8A00-4D35-AD7D-D206794FF1D0

Q35013781-CBFDACAF-D07F-4D1B-8C04-076C6E9F8FB5

Q35013781-D49D8851-CA77-45A9-B323-8E6718A5FDC1

Q35013781-E39FD56B-5D00-4FF6-8EDA-A389E0A7FCF4

Q35013781-EB4BCC8E-F73C-4154-9115-FD88B6B83C45

P2860

Q35013781-0A1E9327-A3BE-4AD2-993E-5D16CBC69260

Q35013781-2B84503E-891B-4843-BD55-DE67EC5C2867

Q35013781-311FEDBA-1627-4FB1-85BA-36272DDCBB81

Q35013781-3963FCC7-CFB0-4B4B-AA08-21B605910CFA

Q35013781-4AC36438-2928-4535-9536-9AF3CB087F9E

Q35013781-5193C7B7-37FB-4644-99F3-CED95B03B1E0

Q35013781-5499F17D-92F0-47CB-84F6-E7E39280C6FD

Q35013781-58688293-BC13-4A8C-9E2C-205AB371B294

Q35013781-5B979F1E-4995-44F2-957A-C1E1AE370F3D

Q35013781-5D3DF7E5-8B52-49C0-93B8-FBC45D10693B

P304

Q35013781-B275304A-35E3-4C68-9C42-106B749774DD

P31

Q35013781-75E5CF0C-4FFA-444B-B64A-4D90E1A522FC

P356

Q35013781-4CE31720-8BC0-46C2-A70D-F26A9746F786

P407

Q35013781-D00ED4E8-6EA7-4122-9984-CA7B67DD9477

P433

Q35013781-A24C15C7-2D8C-45FC-A451-1A58BEB989FC

P478

Q35013781-2D656529-8382-4A37-B2BE-39037016A0A7

P577

Q35013781-3BAB21EE-A6FD-40A7-8507-99B85C2D5B60

P698

Q35013781-1573B76B-E71D-43BD-9F80-677A177D2C09

P932

Q35013781-900E9DFF-4D87-4005-B1BE-968EB509CF8E

P356

AAC.47.6.1929-1935.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Indinavir, efavirenz, and abac ...... iency virus-infected subjects.

@en

P2093

Adult AIDS Clinical Trials Group Protocol 368/886 Study Team

http://www.w3.org/2001/XMLSchema#string

Alan Forrest

http://www.w3.org/2001/XMLSchema#string

Gene D Morse

http://www.w3.org/2001/XMLSchema#string

Hulin Wu

http://www.w3.org/2001/XMLSchema#string

Kathleen E Squires

http://www.w3.org/2001/XMLSchema#string

Margaret A Fischl

http://www.w3.org/2001/XMLSchema#string

Raymond Cha

http://www.w3.org/2001/XMLSchema#string

Robert DiCenzo

http://www.w3.org/2001/XMLSchema#string

Scott M Hammer

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.

Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Cytochrome P450 3A: ontogeny and drug disposition.

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.

P304

1929-1935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.6.1929-1935.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12760869

http://www.w3.org/2001/XMLSchema#string

P932

155818

http://www.w3.org/2001/XMLSchema#string